الفهرس 
hepatic fibrosisOnly 14 pages are availabe for public view
 |  | from | 166 |  |  |
| | | from | 166 | | |
Abstract
Hepatic fibrosis is a reversible wound healing process that results from chronic non-resolving inflammation. It’s mainly due to chronic viral hepatitis B or C, biliary diseases and nonalcoholic steatohepatitis. The most prevalent cause in Egypt is HCV. Once fibrogenesis has progressed to cirrhosis, there is increased risk of developing hepatocellular carcinoma Therefore, antifibrotics that prevent progression toward cirrhosis or induce regression of advanced fibrosis are urgently needed The search for new antifibrotic drugs led us to examine the role of losartan (AT1 receptor blocker) and atorvastatin (an HMG-CoA reductase inhibitor), as promising therapies, in attenuation of hepatic fibrosis progression, either as monotherapy or as combined therapy Hepatic fibrosis was induced by i.p. injection of 50% CCl4 solution in corn oil at a dose of 0.2 mL/100 g twice a week for 8 weeks. Rats were randomly divided into four subgroups, including fibrosis control group and three drug-treated groups with either losartan (LOS; 10 mg/kg, orally) or atorvastatin (ATOR; 10 mg/kg, orally) or a combination of both drugs. The fifth group served as normal control and received the vehicle. Administration of drugs started at the end of the fourth week after being exposed to CCl4 for 4 weeks and continued daily for further 4 weeks.